研究実績

A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS exon 2, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese. Osaka Gastrointestinal cancer chemotherapy Study Group:(OGSG1001)

Taishi Hata, Motoki Yoshida, Koichi Taira, Naotoshi Sugimoto, Yukihiko Tokunaga, Takayuki Kii, Shin Kuwakado, Mutsumi Fukunaga, Hiroko Hasegawa, Takeshi Kato, Yasuhiro Miyake, Koji Takeda, Tetsuhiro Yoshinami, Haruko Daga, Daisuke Sakai, Toshio Shimokawa, Yukinori Kurokawa, Taro Sato, Toshimasa Tsujinaka, Hiroshi Furukawa  ESMO-GI 2014, Barcelona, Spain, 25-28 Jun 2014

前の記事 次の記事 一覧ページへ戻る